Metabolic Disorders: Defects in Biodegradation Pathways - Lysosomal Storage Diseases

Introduction

This section focuses on a group of metabolic disorders known as lysosomal storage diseases. These conditions arise from defects in the biodegradation pathways that normally occur within lysosomes, the cell's "recycling factories." We will explore:

The normal function of lysosomes and the importance of macromolecule turnover.
The nature of glycoproteins and glycolipids, including gangliosides.
The general characteristics of inborn errors of metabolism affecting the degradation of these complex molecules.
Specific examples of lysosomal storage diseases:
- Gaucher's disease (defect in glucosylceramidase).
- Tay-Sachs disease (defect in β-hexosaminidase A).
- Mucopolysaccharidoses, with a focus on Hunter's Disease (defect in iduronate sulphatase).
For each disorder, we will discuss the enzyme defect, inheritance pattern, clinical features, diagnostic approaches, and current or potential treatment strategies.

The Lysosome: The Cell's Recycling Factory

Structure and Function:
- Lysosomes are membrane-bound organelles found in nearly all animal cells.
- They function as the cell's waste disposal and recycling system, responsible for digesting unwanted or obsolete biological molecules, including proteins, nucleic acids, carbohydrates, and lipids.
- They contain over 60 different hydrolytic enzymes (e.g., proteases, nucleases, lipases, glycosidases, sulfatases), each carrying out specific degradative functions.
Optimal pH: The internal environment of the lysosome is acidic, with a pH maintained between 4.5 and 5.0. This acidic pH is optimal for the activity of lysosomal degradative enzymes.

Glycoproteins and Glycolipids: Structure and Turnover

Many complex biological molecules are glycoproteins (proteins with covalently attached sugar chains) or glycolipids (lipids with covalently attached sugar chains).

Glycoproteins:
- Sugars can be linked to proteins via:
  - O-glycosidic bonds: Formed by the reaction of a nucleotide sugar with the hydroxyl group of serine (Ser), threonine (Thr), or hydroxylysine residues. This typically occurs in the Golgi apparatus.
  - N-glycosidic bonds: A more complex process involving a lipid carrier (dolichol phosphate) to assemble an activated oligosaccharide, which is then transferred en bloc to asparagine (Asn) residues within specific consensus sequences. This begins in the endoplasmic reticulum and is further modified in the Golgi.
- Roles: Glycoproteins have numerous biological roles, including antibodies (immunity), fibrinogen (blood clotting), cell surface receptors, and components of the extracellular matrix. They are important in cell recognition and cell-cell interactions.
Glycolipids:
- Derived from lipids like sphingosine, where sugars are attached to the hydroxyl group of the lipid backbone.
- Exclusively found in cellular membranes, with their carbohydrate portions typically exposed on the extracellular surface.
- Roles: Play a role in cell recognition, cell adhesion, and membrane stabilization.
Turnover: Like other biological molecules, glycoproteins and glycolipids are constantly being synthesized and degraded (turned over) as part of normal cellular maintenance and function. Lysosomes are central to their degradation.

Inborn Errors of Metabolism: Lysosomal Storage Diseases (LSDs)

Definition: A group of genetic disorders resulting from defects in lysosomal function, most commonly due to deficiencies in specific lysosomal hydrolytic enzymes.
Pathophysiology:
- When a specific lysosomal enzyme is defective or missing, its substrate (the molecule it normally degrades) cannot be broken down.
- This leads to the progressive accumulation of the undigested substrate within lysosomes, causing them to swell and eventually disrupt normal cell function.
- The accumulation occurs gradually within various tissues and can lead to a wide range of clinical symptoms.
General Clinical Features (can vary widely depending on the specific LSD):
- Gradual accumulation of incompletely degraded oligosaccharides (from glycoproteins or glycolipids) or other macromolecules (e.g., mucopolysaccharides) within tissues and sometimes their excretion in urine.
- Common manifestations can include skeletal abnormalities, hepatosplenomegaly (enlarged liver and spleen), cataracts, and neurological degeneration leading to mental retardation.

Gangliosides and Gangliosidoses

Gangliosides: A specific group of complex glycolipids (glycosphingolipids) found predominantly in neural tissue, constituting up to 6% of the total lipid content in the brain.
- Structure: Composed of a ceramide (a lipid backbone consisting of sphingosine and a fatty acid) linked to an oligosaccharide head group that always contains one or more sialic acid (N-acetylneuraminic acid - NANA) residues.
Gangliosidoses: A subgroup of lysosomal storage diseases caused by defects in the stepwise enzymatic degradation of gangliosides. The accumulation of specific gangliosides leads to severe neurodegenerative disorders.
Degradation Pathway of Gangliosides (Example Steps):
1. (Complex ganglioside, e.g., GM1) Gal-GalNAc-Gal-Glc-Ceramide (with NANA branches)
  - Enzyme: β-galactosidase removes a terminal galactose.
  - Defect leads to: GM1 gangliosidosis.
2. (Product from step 1, GM2 ganglioside) GalNAc-Gal-Glc-Ceramide (with NANA)
  - Enzyme: β-hexosaminidase A removes terminal N-acetylgalactosamine.
  - Defect leads to: GM2 gangliosidosis (e.g., Tay-Sachs disease).
3. (Product from step 2) Gal-Glc-Ceramide (with NANA)
  - Enzyme: Neuraminidase removes sialic acid (NANA).
4. (Product from step 3) Gal-Glc-Ceramide
  - Enzyme: β-galactosidase removes galactose.
  - Defect leads to: Krabbe's disease (globoid cell leukodystrophy).
5. (Product from step 4) Glc-Ceramide (Glucosylceramide or Glucocerebroside)
  - Enzyme: β-glucosidase (glucocerebrosidase or glucosylceramidase) removes glucose.
  - Defect leads to: Gaucher's disease.
6. (Product from step 5) Ceramide (can be further degraded).

Specific Lysosomal Storage Diseases

A. Gaucher's Disease

Biochemical Defect: Deficiency of the lysosomal enzyme glucocerebrosidase (β-glucosidase or glucosylceramidase), which cleaves the glucose residue from glucocerebroside (glucosylceramide).
Consequence: Accumulation of glucocerebroside within the lysosomes of cells, particularly macrophages (which become "Gaucher cells"). These lipid-laden macrophages accumulate in the spleen, liver, bone marrow, and sometimes other tissues.
Inheritance: Autosomal recessive.
Incidence: Most common lysosomal storage disease. Overall incidence is ~1 in 50,000 live births, but much higher in certain populations (e.g., Ashkenazi Jews, where carrier frequency is ~1 in 10 and disease incidence can be 100 times more common than in the general population).
Clinical Features: Characterized by bruising, fatigue (due to anemia), hepatosplenomegaly (enlarged liver and spleen, which are liable to rupture due to processing of blood cells and accumulation of Gaucher cells), bone disease (pain, fractures, osteonecrosis), and in some types, neurological involvement.
Mutations: Numerous mutations (up to 80) have been identified in the GBA gene encoding glucocerebrosidase. The most common is Asn370Ser (N370S).
Subtypes (Severity depends on residual enzyme activity):
- Type 1 (Non-neuropathic):
  - Most common form, particularly prevalent in Ashkenazi Jews.
  - Some residual enzyme activity is present.
  - The brain is generally not affected.
  - Main symptoms: Hepatosplenomegaly, anemia, fatigue, bone problems.
  - Slightly reduced life expectancy.
- Type 2 (Acute Infantile Neuropathic):
  - Severe; symptoms apparent by 6 months of age, including seizures, mental retardation, and rapid neurodegeneration.
  - No or very little residual enzyme activity in lysosomes.
  - A common mutation is Leu444Pro (L444P).
  - Death usually by the age of 3.
- Type 3 (Chronic Neuropathic):
  - Symptoms can appear from early childhood to adulthood.
  - Progressive but less severe neurological symptoms than Type 2.
  - The L444P mutation is also common, but its effects may be delayed or modified by protective polymorphisms or other genetic factors.
  - Found in particular Swedish communities, for example.
  - Death usually by the age of 30.
Compound Heterozygosity: The clinical picture can be complicated by individuals inheriting two different mutant alleles.
Parkinson's Disease Link: Interestingly, Parkinson's disease is more common in patients with Gaucher's disease (especially Type 1) and also in heterozygous carriers of GBA mutations.
Treatment:
- Enzyme Replacement Therapy (ERT): For Type 1 and some non-neurological aspects of Type 3. Involves intravenous infusion of recombinant glucocerebrosidase (e.g., Imiglucerase, Velaglucerase alfa). Very expensive (e.g., £200,000 per annum). Currently no effective treatment for the neurological symptoms of Type 2 or Type 3.
- Substrate Reduction Therapy (SRT): Involves drugs that inhibit the synthesis of glucocerebroside, thereby reducing the amount of substrate that accumulates (e.g., Miglustat, Eliglustat). Approved for some Type 1 patients.

B. Tay-Sachs Disease (GM2 Gangliosidosis)

Biochemical Defect: Deficiency of the lysosomal enzyme β-hexosaminidase A (HexA). This enzyme is composed of α and β subunits; Tay-Sachs is typically caused by mutations in the HEXA gene encoding the α-subunit. HexA is responsible for cleaving a terminal N-acetylgalactosamine residue from GM2 ganglioside.
Consequence: Accumulation of GM2 ganglioside, primarily in the lysosomes of neurons in the brain and central nervous system.
Inheritance: Autosomal recessive.
Incidence: ~1 in 320,000 in the general population. Considerably higher in certain populations like Ashkenazi Jews (carrier frequency ~1 in 27-30, disease incidence up to 1 in 3,600-4,000 births), French Canadians, and Cajuns from Louisiana.
Mutations: More than 100 different mutations in the HEXA gene have been identified.
Diagnosis:
- Initially via enzyme assay (measuring HexA activity in serum or leukocytes). This was the first metabolic disorder for which a rapid/inexpensive test for mass carrier screening was developed, serving as a model.
- Genetic testing for specific mutations.
- Characteristic "cherry-red spot" on the macula of the retina (visible on eye examination) due to ganglioside accumulation in retinal ganglion cells.
Subtypes (Based on age of onset and severity, often related to residual HexA activity):
- Infantile TSD (Classic):
  - Most common and severe form.
  - Infants appear normal at birth and for the first few months.
  - Relentless deterioration of mental and physical abilities begins after about six months, including progressive weakness, loss of motor skills, exaggerated startle response, seizures.
  - Child becomes blind, deaf, and paralytic.
  - Death usually by the age of 5.
  - A common mutation in Ashkenazi Jews is a four-base pair insertion in exon 11 of the HEXA gene, leading to a frameshift and premature stop codon.
- Juvenile TSD:
  - Extremely rare.
  - Onset between 2 and 10 years of age.
  - Slower progression than infantile form, but still leads to neurodegeneration (ataxia, dysarthria, cognitive decline, seizures).
  - Death usually between 5 and 15 years.
- Late-Onset TSD (LOTS) / Adult-Onset TSD:
  - Symptoms begin in adolescence or early adulthood (20s-30s), but can occur later.
  - Usually non-fatal, or at least much slower progression.
  - Characterized by progressive neurological deterioration (e.g., muscle weakness, ataxia, dysarthria, tremor), psychiatric symptoms (psychotic episodes, depression, bipolar disorder), and cognitive difficulties.
  - Individuals are often wheelchair-bound in later stages.
  - Often due to mutations that allow for some residual HexA enzyme activity.
Compound Heterozygosity: Often explains the variability in severity and age of onset, as individuals may inherit two different mutant alleles with varying impacts on enzyme function.
Treatment and Prevention:
- Currently no cure or effective treatment. ERT is difficult due to the blood-brain barrier, which prevents the enzyme from reaching the brain. SRT has had limited success to date. Gene therapy is being explored (e.g., using a Jacob sheep model which has a similar gangliosidosis).
- Prevention:
  - Carrier screening in high-risk populations.
  - Prenatal diagnosis (amniocentesis or chorionic villus sampling).
  - Preimplantation Genetic Diagnosis (PGD) for couples undergoing IVF.
  - Mate selection based on carrier status (historically significant in some communities).

C. Mucopolysaccharidoses (MPS Disorders)

Definition: A group of genetic lysosomal storage disorders characterized by the accumulation of glycosaminoglycans (GAGs), also known as mucopolysaccharides, due to deficiencies in specific lysosomal enzymes required for their stepwise degradation.
Pathophysiology: The undegraded or partially degraded GAGs (primarily dermatan sulphate, heparan sulphate, keratan sulphate, chondroitin sulphate – but not hyaluronan which is degraded differently) accumulate in lysosomes of various tissues.
Clinical Features: Accumulation leads to a wide range of progressive symptoms, including coarse facial features, skeletal abnormalities (dysostosis multiplex), joint stiffness, organomegaly (hepatosplenomegaly), corneal clouding, hearing loss, cardiac problems, and often neurological involvement (mental retardation, neurodegeneration). Severity varies greatly depending on the specific MPS type and the residual enzyme activity. Death can occur in severe cases.

Hunter's Disease (Mucopolysaccharidosis Type II - MPS II)

Biochemical Defect: Deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which is required for the degradation of dermatan sulphate and heparan sulphate.
Consequence: Accumulation of dermatan sulphate and heparan sulphate in lysosomes.
Inheritance: X-linked recessive (one of the few X-linked LSDs, mainly affecting males).
Incidence: Very rare.
Clinical Features:
- Onset: Difficult to diagnose early. Signs usually begin around 1-4 years of age as GAGs accumulate.
- Physical Features: Coarse facial features (e.g., broad nose, thick lips), large head (macrocephaly), enlarged tongue (macroglossia), distended abdomen (due to hepatosplenomegaly).
- Progressive Symptoms: Joint stiffness, skeletal deformities, short stature, hearing loss, cardiac valve problems.
- Neurological Involvement: Brain development is often affected, leading to developmental delay and progressive mental retardation in severe forms.
- Forms:
  - Severe Form: Rapid progression, significant neurodegeneration, respiratory problems, death usually before adulthood (often by teens).
  - Milder (Attenuated) Form: Slower progression, less severe or absent neurological involvement, individuals may live into their 30s or beyond, though still with significant morbidity.
Treatment:
- Enzyme Replacement Therapy (ERT): Available for the less severe (attenuated) form (e.g., Idursulfase). It can improve some somatic symptoms but does not effectively cross the blood-brain barrier to address neurological aspects.
- Gene Therapy: Clinical trials are underway. For example, a trial in the US for an FDA-approved gene therapy treatment was mentioned for a 44-year-old male with a milder version. Successful gene therapy for MPS II (and other LSDs with CNS involvement) would be a major breakthrough, especially if it can deliver the enzyme to the brain.

Learning Outcomes Summary

This lecture aimed to provide an understanding of:

The principle that biological molecules (like glycoproteins, glycolipids, and GAGs) are continuously turned over (synthesized and degraded).
That lysosomes are specific organelles containing a battery of hydrolytic enzymes, acting as the recycling factories within the cell, essential for this biodegradation.
How defects in specific lysosomal enzymes lead to the accumulation of undigested substrates, resulting in lysosomal storage diseases (LSDs).
The inheritance patterns (mostly autosomal recessive, Hunter's is X-linked recessive) and the biochemical basis of specific LSDs like Gaucher's disease, Tay-Sachs disease, and Hunter's disease.
How knowledge of the biochemistry of these pathways and the nature of the enzyme defects informs the clinical symptoms observed, diagnostic approaches (enzyme assays, genetic testing), and the development of treatment options (e.g., ERT, SRT, potential for gene therapy).
The concept that the severity of LSDs often correlates with the amount of residual enzyme activity, and how factors like compound heterozygosity can contribute to phenotypic variability.